FDA OKs Mallinckrodt NDA for knee treatment

|About: Mallinckrodt PLC (MNK)|By:, SA News Editor

The FDA has approved Mallinckrodt's (MNK) NDA for Pennsaid 2%, a topical non-steroidal anti-inflammatory treatment for osteoarthritis of the knee.

U.S. sales and marketing rights for Pennsaod are licensed to Mallinckrodt by Nuvo Research (NRIFF).

The approval comes with warnings about the risks of non-steroidal anti-inflammatories to the heart and the rest of the cardiovascular system, and to the liver. (PR)